Title:
A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb 004, a Humanized Monoclonal Antibody, in Subjects with Solid Tumors
Protocol Number:
J08135
Phase:
Phase I
Physician:
Luis Diaz
Purpose:
To determine the safety, side effects and highest tolerated dose of MORA-b-004, a humanized monoclonal antibody, in subjects with solid tumors
Eligibility:
greater than 18 years with solid tumor malignancy; no brain mets; cannot be on anticoagulants (blood thinners); at least 3 weeks since prior chemo; no serious infections; no other active maliganancies
Treatment:
Patient will receive weekly infusions of MORAb-004-001 for 1 cycle (4 weeks). Patients can continue to receive additional cycles as long as they do not have disease progression. Patient will participate in follow-up visits for three months after final visit.
Population:
Adult
Last Update
05/21/2013 04:02 AM
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts